Cabaletta Bio Inc

NASDAQ:CABAUnited States

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Contact Information

Headquarters

2929 Arch Street, Suite 600PHILADELPHIA, PA, United States 19104

Phone

267-759-3100

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Steven Nichtberger

Chief Financial Officer

Anup Marda

President - Science and Technology

Gwendolyn Binder-Scholl

General Counsel, Secretary

Michael Gerard

Chief Medical Officer

David Chang